U.S. Markets close in 2 hrs 45 mins

Free Research Report as DexCom’s Quarterly Revenues Surged 29%; Turned Profitable Y-O-Y

Stock Monitor: Cancer Genetics Post Earnings Reporting

LONDON, UK / ACCESSWIRE / April 10, 2018 / Active-Investors.com has just released a free earnings report on DexCom, Inc. (NASDAQ: DXCM). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=DXCM. The Company reported its fourth quarter fiscal 2017 and full fiscal year 2017 operating and financial results on February 27, 2018. The medical device Company outperformed top- and bottom-line expectations. Additionally, the Company provided guidance for the full year FY18. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Cancer Genetics, Inc. (NASDAQ: CGIX), which also belongs to the Healthcare sector as the Company DexCom. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=CGIX

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, DexCom most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=DXCM

Earnings Highlights and Summary

For the fourth quarter of the fiscal year 2017, DexCom's revenues were $221.0 million, reflecting an increase of 29% from $171.2 million in Q4 2016, and resulting in the Company's strongest growth quarter of the year. DexCom's revenue numbers beat analysts' estimates of $217.8 million.

During Q4 2017, DexCom's US revenues surged 25% to $187.8 million on a y-o-y basis, and represented 85% of the Company's overall revenues. The International Company's revenues totaled $33.2 million, reflecting a growth of 58% on a y-o-y basis.

During Q4 2017, DexCom recorded a gross profit of $153.5 million, resulting in a gross margin of 69%, compared to $116.7 million, or 68% of revenues, in Q4 2016. The Company's operating expenses totaled $142 million in the reported quarter compared to $123 million in the prior year's same quarter.

For Q4 2017, DexCom recorded a GAAP net loss of $9.4 million, or $0.11 loss per share, compared to a GAAP net loss of $7.4 million, or $0.09 loss per share, in Q4 2016. The Company's reported quarter results included net non-cash expenses of $55.7 million, comprised primarily of share-based compensation, depreciation and amortization, non-cash interest expenses related to its senior convertible notes, and a non-cash tax expense of $18.2 million related to the reversal of a non-cash deferred tax benefit. DexCom's Q4 2016 results consisted of non-cash expenses of $34.3 million, comprised primarily of share-based compensation, and depreciation and amortization.

DexCom's non-GAAP net income was $8.8 million, or $0.10 per share, in Q4 2017 compared to a non-GAAP net loss of $7.4 million, or $0.09 loss per share, in Q4 2016. The Company's earnings numbers surpassed Wall Street's estimates of $0.03 per share.

DexCom's revenues grew to $718.5 million during the full fiscal year 2017, reflecting an increase of 25% from $573.3 million in FY16.

For FY17, DexCom recorded a GAAP net loss of $50.2 million, or $0.58 loss per share, including net non-cash expenses of $139.6 million, compared to a GAAP net loss of $65.6 million, or $0.78 loss per share, for FY16, which included non-cash expenses of $128.1 million.

Cash Matters

As of December 31, 2017, DexCom had $548.6 million in cash, cash equivalents, and short-term marketable securities.

Annual Guidance

For the full fiscal year 2018, DexCom is forecasting revenues to be in the range of $830 million to $850 million; gross profit margin to be in the band of 65% to 68%; and GAAP operating expenses, excluding investments into non-intensive programs, to grow 10% versus FY17.

Stock Performance Snapshot

April 09, 2018 - At Monday's closing bell, DexCom's stock slightly rose 0.33%, ending the trading session at $70.38.

Volume traded for the day: 1.30 million shares, which was above the 3-month average volume of 1.20 million shares.

Stock performance in the last month – up 16.91%; previous three-month period – up 32.14%; past six-month period – up 46.62%; and year-to-date – up 22.63%

After yesterday's close, DexCom's market cap was at $6.30 billion.

Price to Earnings (P/E) ratio was at 111.89.

The stock is part of the Healthcare sector, categorized under the Medical Laboratories & Research industry. This sector was up 1.1% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors